Solid Tumor Malignancies: Clinical Trials

2 recruiting. 2 Phase 4.

By phase and status

Phase	Trials	Status
Phase 4	2	Recruiting 2

Follow Solid Tumor Malignancies: new trials by email Literature Review of Solid Tumor Malignancies trials Research Report on Solid Tumor Malignancies

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors Pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive - NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer	Phase 4	Recruiting	Rigel Pharmaceuticals	12	2026-03-04	2026-08-10
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates - AML (Acute Myeloid Leukemia), Glioma	Phase 4	Recruiting	Rigel Pharmaceuticals	16	2026-02-23	2026-08-11

Narrower conditions

Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Cholangiocarcinoma (1)  ·  Glioma (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Thyroid Neoplasms (1)

Broader conditions

Adenocarcinoma (1)  ·  Bronchial Neoplasms (1)  ·  Carcinoma (1)  ·  Carcinoma, Bronchogenic (1)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)  ·  Head and Neck Neoplasms (1)  ·  Hematologic Diseases (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Leukemia (1)  ·  Leukemia, Myeloid (1)  ·  Lung Diseases (1)  ·  Lung Neoplasms (1)  ·  Neoplasms by Histologic Type (1)  ·  Neoplasms by Site (1)

Interventions

Cytochrome P-450 CYP2C8 (2)  ·  Cytochrome P-450 CYP3A (2)  ·  Cytochrome P-450 CYP1A2 (1)  ·  Cytochrome P-450 CYP2B6 (1)  ·  Cytochrome P-450 CYP2C19 (1)  ·  Cytochrome P-450 CYP2C9 (1)  ·  olutasidenib (1)  ·  pralsetinib (1)

Sponsors

Rigel Pharmaceuticals (2)

Countries

Spain (1)  ·  United States (1)